Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : progenics -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (119)	8/27/2008 1:15:22 PM
From: tom pope	Read Replies (1) \| Respond to of 139

Do you know of any reason for today's move? Don't own any.

To: tuck who wrote (119)	1/26/2009 3:10:00 PM
From: tuck	Read Replies (1) \| Respond to of 139

Relistor sales still looking lackluster, and with WYE being munched by PFE, I don't know what to think of sales efforts going forward. PGNX reports $1.5 million of Relistor sales in Q4. Though that's a huge percentage improvement over Q3, which was $800,000, there's a long ways to go before they get meaningful for PGNX. All depends on what Pfizer does with the WYE assets, but rationalizing that might take some time. PGNX started the day of well, but on releasing the above number, is off now. I have a long position via sold puts, which will be OK if it can hold the $7s. Cheers, Tuck